The World Health Organization (WHO) has recommended LFA—a strategy shown to be cost-effective [7]—for detecting CrAg as screening in AIDS patients with low CD4+ cell count in regions with a prevalence of cryptococcosis greater than 3%. The gene discussed is CD4; the disease is cryptococcosis.